Home > News > Headline News > Archive

Click on title to read the full article.

Tackling a Racial Gap in Breast Cancer Survival

December 20, 2013

By Tara Pope-Parker, New York Times

MEMPHIS — After her doctor told her two months ago that she had breast cancer, Debrah Reid, a 58-year-old dance teacher, drove straight to a funeral home. She began planning a burial with the funeral director and his wife, even requesting a pink coffin.

Sensing something was amiss, the funeral director, Edmund Ford, paused. “Who is this for?” he asked. Ms. Reid replied quietly, “It’s for me.”

Dasatinib Added to Aromatase Inhibitor Extends PFS in HER2-Negative MBC - See more at: http://www.onclive.com/conference-coverag

December 18, 2013

By Onc Live

Adding the tyrosine kinase inhibitor dasatinib to standard aromatase inhibitor therapy with letrozole doubled progression-free survival (PFS) compared with letrozole alone in women with hormone receptor-positive, HER2-negative metastatic breast cancer. The PFS endpoint was an exploratory secondary endpoint of a phase II noncomparative clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.
- See more at: http://www.onclive.com/conference-coverage/sabcs-2013/Dasatinib-Added-to-Aromatase-Inhibitor-Extends-PFS-in-HER2-Negative-MBC?utm_source=Informz&utm_medium=OncLive&utm_campaign=SABCS%20(Faslodex)%2012-13-13#sthash.wZLyUTRF.dpuf

Dasatinib may inhibit AI resistance in metastatic breast cancer

December 14, 2013

By Healio

Dasatinib inhibited aromatase inhibitor resistance in postmenopausal women with locally recurrent or metastatic breast cancer, according to results of a small phase 2 study presented at the San Antonio Breast Cancer Symposium.